Literature DB >> 20595524

Long-term survival after nonintensive chemotherapy in some juvenile myelomonocytic leukemia patients with CBL mutations, and the possible presence of healthy persons with the mutations.

Kazuyuki Matsuda, Chiaki Taira, Kazuo Sakashita, Shoji Saito, Miyuki Tanaka-Yanagisawa, Ryu Yanagisawa, Yozo Nakazawa, Masaaki Shiohara, Keitaro Fukushima, Megumi Oda, Takayuki Honda, Tatsutoshi Nakahata, Kenichi Koike.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20595524     DOI： 10.1182/blood-2009-12-260729

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  8 in total

1.  CBL mutations in myeloproliferative neoplasms are also found in the gene's proline-rich domain and in patients with the V617FJAK2.

Authors:  Paula Aranaz; Cristina Hurtado; Ignacio Erquiaga; Itziar Miguéliz; Cristina Ormazábal; Ion Cristobal; Marina García-Delgado; Francisco Javier Novo; José Luis Vizmanos
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

Review 2.  RAS diseases in children.

Authors:  Charlotte M Niemeyer
Journal:  Haematologica       Date:  2014-11       Impact factor: 9.941

3.  Management of Two Juvenile Myelomonocytic Leukemia Patients According to Clinical and Genetic Features.

Authors:  Özlem Tüfekçi; Hale Ören; Fatma Demir Yenigürbüz; Salih Gözmen; Tuba Hilkay Karapınar; Gülersu İrken
Journal:  Turk J Haematol       Date:  2015-06       Impact factor: 1.831

4.  Anti-proliferative effects of T cells expressing a ligand-based chimeric antigen receptor against CD116 on CD34(+) cells of juvenile myelomonocytic leukemia.

Authors:  Yozo Nakazawa; Kazuyuki Matsuda; Takashi Kurata; Akane Sueki; Miyuki Tanaka; Kazuo Sakashita; Chihaya Imai; Matthew H Wilson; Kenichi Koike
Journal:  J Hematol Oncol       Date:  2016-03-16       Impact factor: 17.388

5.  Juvenile Myelomonocytic Leukemia in Turkey: A Retrospective Analysis of Sixty-five Patients.

Authors:  Özlem Tüfekçi; Ülker Koçak; Zühre Kaya; İdil Yenicesu; Canan Albayrak; Davut Albayrak; Şebnem Yılmaz Bengoa; Türkan Patıroğlu; Musa Karakükçü; Ekrem Ünal; Elif Ünal İnce; Talia İleri; Mehmet Ertem; Tiraje Celkan; Gül Nihal Özdemir; Nazan Sarper; Dilek Kaçar; Neşe Yaralı; Namık Yaşar Özbek; Alphan Küpesiz; Tuba Karapınar; Canan Vergin; Ümran Çalışkan; Hüseyin Tokgöz; Melike Sezgin Evim; Birol Baytan; Adalet Meral Güneş; Deniz Yılmaz Karapınar; Serap Karaman; Vedat Uygun; Gülsun Karasu; Mehmet Akif Yeşilipek; Ahmet Koç; Erol Erduran; Berna Atabay; Haldun Öniz; Hale Ören
Journal:  Turk J Haematol       Date:  2017-02-09       Impact factor: 1.831

Review 6.  Role of CBL Mutations in Cancer and Non-Malignant Phenotype.

Authors:  Davide Leardini; Daria Messelodi; Edoardo Muratore; Francesco Baccelli; Salvatore N Bertuccio; Laura Anselmi; Andrea Pession; Riccardo Masetti
Journal:  Cancers (Basel)       Date:  2022-02-08       Impact factor: 6.639

Review 7.  Genomic and Epigenomic Landscape of Juvenile Myelomonocytic Leukemia.

Authors:  Claudia Fiñana; Noel Gómez-Molina; Sandra Alonso-Moreno; Laura Belver
Journal:  Cancers (Basel)       Date:  2022-03-04       Impact factor: 6.639

8.  The genomic landscape of juvenile myelomonocytic leukemia.

Authors:  Elliot Stieglitz; Amaro N Taylor-Weiner; Tiffany Y Chang; Laura C Gelston; Yong-Dong Wang; Tali Mazor; Emilio Esquivel; Ariel Yu; Sara Seepo; Scott Olsen; Mara Rosenberg; Sophie L Archambeault; Ghada Abusin; Kyle Beckman; Patrick A Brown; Michael Briones; Benjamin Carcamo; Todd Cooper; Gary V Dahl; Peter D Emanuel; Mark N Fluchel; Rakesh K Goyal; Robert J Hayashi; Johann Hitzler; Christopher Hugge; Y Lucy Liu; Yoav H Messinger; Donald H Mahoney; Philip Monteleone; Eneida R Nemecek; Philip A Roehrs; Reuven J Schore; Kimo C Stine; Clifford M Takemoto; Jeffrey A Toretsky; Joseph F Costello; Adam B Olshen; Chip Stewart; Yongjin Li; Jing Ma; Robert B Gerbing; Todd A Alonzo; Gad Getz; Tanja Gruber; Todd Golub; Kimberly Stegmaier; Mignon L Loh
Journal:  Nat Genet       Date:  2015-10-12       Impact factor: 38.330
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.